Results 1 to 10 of about 5,010,567 (251)

Bladder cancer [PDF]

open access: yesNature Reviews Disease Primers, 2020
Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after ...
Oner Sanli   +6 more
semanticscholar   +6 more sources

Epidemiology of Bladder Cancer [PDF]

open access: yesMedical Sciences, 2020
Based on the latest GLOBOCAN data, bladder cancer accounts for 3% of global cancer diagnoses and is especially prevalent in the developed world. In the United States, bladder cancer is the sixth most incident neoplasm.
Kalyan Saginala   +5 more
semanticscholar   +4 more sources

Bladder Cancer [PDF]

open access: yesCurrent Treatment Options in Oncology, 2009
Bladder cancer is a complex disease of older patients with coexisting medical problems requiring multimodal therapy. For patients with localized bladder cancer, standard management for superficial disease includes transurethral resection with or without intravesical therapy, while muscle-invasive cancer is managed with neoadjuvant cisplatin- based ...
David J. Gallagher, Matthew I. Milowsky
  +10 more sources

Bladder cancer [PDF]

open access: yesNature Reviews Disease Primers, 2023
Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways depending on whether the disease is non-muscle invasive or muscle invasive. The mutational burden is higher in muscle-invasive than in non-muscle-invasive disease.
Lars Dyrskjøt   +6 more
openaire   +2 more sources

Bladder Cancer [PDF]

open access: yesThe Scientific World JOURNAL, 2011
To review the epidemiology, diagnosis, and management of all stages of bladder cancer with an emphasis on studies published within the last year.Smoking continues to be the most important risk factor for the development of bladder cancer, and this risk has increased over time.
Todd M, Morgan   +2 more
openaire   +5 more sources

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning

open access: yesFrontiers in Surgery, 2022
IntroductionNon-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease; many patients develop recurrent or progress to muscle-invasive disease.
Kelly Ward   +4 more
doaj   +1 more source

STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes

open access: yesEuropean Urology Open Science, 2022
Background: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest that ...
Naheema S. Gordon   +9 more
doaj   +1 more source

CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer

open access: yesMolecular Cancer, 2023
Background Bladder cancer (BCa) is the fourth most common malignant tumor with a poor prognosis worldwide. Further exploration and research are needed to unmask the underlying roles and molecular mechanisms of circular RNAs.
Boda Xie   +9 more
semanticscholar   +1 more source

Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes

open access: yesGenome Medicine, 2022
Background Three-quarters of bladder cancer patients present with early-stage disease (non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however, most next-generation sequencing studies to date have concentrated on later-stage ...
Anshita Goel   +16 more
doaj   +1 more source

PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium

open access: yesFrontiers in Oncology, 2021
The use of immune checkpoint blockade, in particular PD-1 and PD-L1 inhibitors, is now commonplace in many clinical settings including the treatment of muscle-invasive bladder cancer (MIBC).
Alexander C. Dowell   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy